Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZN-F-6418
- Development stage
- Phase 1
- Lead developer
- Suzhou Zanrong Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZN-F-6418 is an orally bioavailable small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, specifically targeting FGFR2 and FGFR3. Developed by Suzhou Zanrong Pharma, the compound is designed to treat advanced solid tumors that harbor FGFR alterations, such as gene fusions, mutations, or amplifications. By selectively inhibiting FGFR signaling, ZN-F-6418 disrupts downstream oncogenic pathways, including the RAS-MAPK and PI3K-AKT cascades, which are critical for tumor cell proliferation and survival. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and preliminary therapeutic activity in patients with refractory solid malignancies.
02
Targets
FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on ZN-F-6418.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZN-F-6418.